Acambis is developing an investigational smallpox vaccine, ACAM2000.
DHHS determined that Acambis' technical proposal was no longer in the competitive range for award, and to-date, DHHS has not provided a specific reason for the decision.
In the MVA-related litigation between Acambis and Bavarian Nordic A/S (BN),
the International Trade Commission (ITC) has decided to review the judge's Initial Determination. Acambis received a favourable judgement in September, invalidating the patent claims made against Acambis by BN.
Acambis said it expects a favourable ruling, given the strength of the ruling in September and of the ITC staff's independent view of the case. The final decision is expected in January 2007.
source - AFX